Nicox Sa · EURONEXT:ALCOX
Nicox Sa — Investor Presentation (April 2026)
25 slides from Nicox Sa's investor presentation, Apr 30, 2026
Slide 1: Nicox Corporate Presentation
Euronext Growth Paris (Ticker symbol: ALCOX) Nicox Corporate Presentation An international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health April 30, 2026
Slide 2: Forward-Looking Statements
Forward - Looking Statements This document has been prepared by Nicox SA and may not be reproduced or distributed, in whole or in part. The information contained in this document has not been independently verified and no representation, warranty or undertaking, expressed or implied, is made as to,
Slide 3: Nicox at a glance
Nicox at a glance Revenue - generating ophthalmology biotech developing sight - saving therapies Late-stage program Commercial-stage Global reach NICOX visible science Significant market in glaucoma with assets and R&D with top-tier opportunity: 80 mn NDA1 filing targeted collaborations worldwide gl
Slide 4: Corporate highlights
Corporate highlights A Proven Strategic NCX 470 : Large Potential Track Transaction NDA in Market for Record Capability preparation NCX 470 NICOX visible science Two commercialized Corporate team Positive pre-NDA ~$7 bn worldwide products in the U.S., with significant meeting held in glaucoma market
Slide 5: Nicox Portfolio: Track Record of Ophthalmology Innovation
Nicox Portfolio: Track Record of Ophthalmology Innovation Near Term Value through NCX 470, a Derisked Product Candidate with Global Potential Preclinical Clinical NDA Marketed Partner VYZULTA® Glaucoma and Ocular Worldwide1 NICOX visible science Latanoprostene Bunod Hypertension Ophthalmic Sol. 0.02
Slide 6: Glaucoma: a Significant Worldwide Ophthalmic Disease
Glaucoma: a Significant Worldwide Ophthalmic Disease Elevated IOP 1 Contributes to Irreversible Optic Nerve Damage, Leading to Progressive Vision Loss NICOX visible science As published in the landmark EMGT study “…each mmHg of decreased IOP was related to an approximately 10% lowering [of risk of v
Slide 7: Unmet Medical Needs for Glaucoma Treatment
Unmet Medical Needs for Glaucoma Treatment 40% of patients Many patients Tolerability issues Despite having well do not achieve require >1 with some established first-line therapies, their target IOP medication medications lead to NICOX visible science including the standard-of-care, on existing whi
Slide 8: NCX 470 highlights and market
NCX 470 highlights and market • Novel, fast acting molecule demonstrating best-in-class IOP lowering efficacy of up to 10mmHg from baseline • Positive pivotal Phase 3 topline results NICOX visible science from the Mont Blanc 1 and Denali 2 trials – NDA ready NCX 470 • Preclinical data suggests poten
Slide 9: Lowers IOP via a Validated Dual Mechanism Pathway
NCX 470 Lowers IOP via a Validated 1 Dual Mechanism Pathway Clinically Validated in Two Phase 3 trials, and Dual Mechanism Proven in a Phase 3b Two Pathways for Aqueous Humor 1 Primary or conventional outflow normally Stimulated by nitric oxide (NO) Outflow accounts for ~60% to NICOX visible science
Slide 10: Preparing for NDA submission in U.S. and China
NCX 470 Preparing for NDA submission in U.S. and China August 2025 Summer 2026 2027 NICOX visible science Topline Results of NDA submission Potential approval Denali Phase 3 in the United and launch in the Clinical Trial States United States • Positive pre-NDA meeting held with U.S. FDA • Chinese ND
Slide 11: Clinical Program
NCX 470 Clinical Program Primary objective of non - inferiority met, supporting NDA submission Image for illustrative purposes only N = 691 56 clinical sites in the U.S. & one site in China Phase 3 studies were Mont Blanc1 NICOX visible science Adaptive design selected the 0.1% designed to demonstra
Slide 12: Phase 3 Trial Design – Efficacy Assessment Period
NCX 470 Phase 3 Trial Design 1 – Efficacy Assessment Period NCX 470 vs. standard of care, Latanoprost Randomized, controlled, double-masked, parallel design trial. Patients with open angle glaucoma or ocular hypertension were randomized 1:1 to once-daily treatment with NCX 470 0.1% or latanoprost 0.
Slide 13: Rapid and Sustained IOP-Lowering Effects
Rapid and Sustained IOP - Lowering Effects Demonstrated in two Phase 3 studies Mont Blanc1 Denali2 NICOX visible science • NCX 470 0.1%: N = 328 Latanoprost 0.005%: N = 333 • NCX 470 0.1%: N = 348 Latanoprost 0.005%: N = 348 • IOP-Lowering from Baseline was 8.0 to 9.7 mmHg for • IOP-Lowering from Ba
Slide 14: Phase 3 Results Confirm Robust Efficacy
NCX 470 Phase 3 Results Confirm Robust Efficacy 1,2,3 Based on Topline Results from both Pivotal Trials 4 • IOP-lowering effect from baseline was 7.9 - 10.0 mmHg for NCX 470 vs. 7.1 to 9.8 mmHg for latanoprost in the trials. NICOX visible science • Statistical non-inferiority was met vs. latanoprost
Slide 15: Well Tolerated in Both Phase 3 Trials
NCX 470 Well Tolerated in Both Phase 3 Trials 1,2,3 No ocular or non ocular serious adverse events related to NCX 470 Mont Blanc Denali NCX 470 Latanoprost NCX 470 Latanoprost NICOX visible science Ocular Hyperemia Conjunctival Hyperemia Hyperemia (most common adverse effect) 11.9% 3.3% 22.0% 9.2% L
Slide 16: Post hoc Data Further Differentiates vs. Standard of Care
NCX 470 Post hoc Data Further Differentiates vs. Standard of Care All Comparisons Are Based on NCX 470 0.1% and Latanoprost 0.005% in Mont Blanc 1,2 • Statistically significantly greater percentage of patients achieve ≤ 18mmHg IOP on NCX 470 compared to latanoprost NICOX visible science • Mean perce
Slide 17: Publications and Presentations
NCX 470 – Publications and Presentations A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and NICOX visible science Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension: The DENALI Trial Authors: S. Asrani, MD, Professor of Ophthalmology, and D. Hubatsch,
Slide 18: Global Licensing of NCX 470
Global L icensing of NCX 470 United States Japan Partnership Partnership with with Kowa Kowa NDA filing Phase 3 trials expected in ongoing summer 2026 NICOX visible science China, Korea and Southeast Asia Partnership with Ocumension NDA to be filed based on U.S. package Rest of World Partnership wit
Slide 19: Kowa – NCX 470 Partnership
Kowa – NCX 470 Partnership Two value - creating deals • Founded in Japan in 1894; Active worldwide February 2024 July 2025 in multiple domains including life sciences 1 • ~8000 employees with an annual group revenue United States NICOX visible science and all territories outside of $4.9 billion Japa
Slide 20: Ocumension - NCX 470 Partnership
Ocumension - NCX 470 Partnership Shareholder of Nicox and Commercial partner for ZERVIATE China • Chinese company created in 2018 and dedicated December 2018 to ophthalmology1 • Listed on the Hong Kong stock exchange China, NICOX visible science since 2020 - ~$800 million market cap Korea, Southeast
Slide 21: Commercial Products and Partnerships
Commercial Products and Partnerships NICOX visible science Same mechanism 5% to 9% royalties 8% to 15% royalties of action as on annual net sales on annual net NCX 470 in China1 sales in the U.S. 2 Launched in over 15 First Commercial Launched3 in countries including sale in China the U.S. the U.S.4
Slide 22: Glaukos - Research Collaboration on NCX 1728
Glaukos - Research Collaboration on NCX 1728 NO-donating PDE5 inhibitor Combining NO-mediated MOA is enhanced NO-Release and prolonged by concomitant with PDE5 phosphodiesterase-5 (PDE5) Inhibition inhibition within the same molecule NICOX visible science NO is an important mediator in both IOP Pote
Slide 23: Financial information
Financial information Nicox is listed on Euronext Growth Paris (Ticker symbol: ALCOX) NICOX visible science Cash runway1 Analyst coverage Financial Information (links): 12+ months Yi Chen Annual Report 2025 HC Wainwright Financial Results 2025 Shareholding Structure & Monthly Share Reporting 23 1. A
Slide 24: Corporate highlights
Corporate highlights A Proven Strategic NCX 470 : Large Potential Track Transaction NDA in Market for Record Capability preparation NCX 470 NICOX visible science Two commercialized Corporate team Positive pre-NDA ~$7 bn worldwide products in the U.S., with significant meeting held in glaucoma market
Slide 25: Nicox S.A.
Euronext Growth Paris (Ticker symbol: ALCOX) Nicox S.A. Sundesk Sophia Antipolis Emerald Square Bâtiment C rue Evariste Galois 06410 Biot, France T: +33 (0)4 97 24 53 00 communications@nicox.com www.nicox.com